Skip to Main Content

INFORMATION FOR

Tumor-induced Osteomalacia Disease Monitoring Program

Conditions

Diseases of the Musculoskeletal System

What is the purpose of this trial?

he objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.

  • Trial with
    Ultragenyx Pharmaceutical, Inc.
  • Start Date
    06/06/2022
  • End Date
    02/28/2031

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000030693